{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T17:28:04Z","timestamp":1786728484022,"version":"build-2736575974"},"reference-count":16,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"Suppl 1","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Brolucizumab is a new anti-vascular endothelial growth factor (anti-VEGF) in the treatment of neovascular age-related macular degeneration (nAMD) and idiopathic polypoidal choroidal vasculopathy (IPCV).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>A retrospective, consecutive, interventional study was conducted from a tertiary eye hospital, in which treatment-na\u00efve and treatment-switch patients were included. They underwent an intravitreal injection of brolucizumab. The decision to reinject was made based on the presence of fluid on spectral domain optical coherence tomography (SD-OCT) or worsening of vision at follow-up. Outcome measures were changes in best-corrected visual acuity (BCVA), central subfield thickness (CST), fluid (subretinal\/intraretinal\/sub-retinal pigment epithelium fluid) levels, and OCT biomarkers and safety analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>\n                      A total of 59 eyes of 50 patients with a total of 132 intravitreal injections were included. There was a statistically significant improvement (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      &lt; 0.05) in BCVA from baseline in logMAR treatment-na\u00efve patients (mean BCVA at baseline 0.6 \u00b1 0.41 and 0.37 \u00b1 0.56). The mean baseline CST of all patients significantly reduced from 582.92 \u00b1 233.11 \u00b5m at baseline to 474.06 \u00b1 252.89 \u00b5m at the final treatment visit. Thirty-eight percent of patients showed complete resolution of SHRM after a single injection. The interval between each subsequent injection increased from a mean of 67 to 96 days in treatment-switch patients and from 47 to 151 days in treatment-na\u00efve patients.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Brolucizumab promises reduced number of injections with longer treatment intervals.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/ijo.ijo_927_23","type":"journal-article","created":{"date-parts":[[2023,12,22]],"date-time":"2023-12-22T01:03:21Z","timestamp":1703207001000},"page":"S33-S36","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Brolucizumab in age-related macular neovascularization (BRAIN study): Efficacy, optical coherence tomography biomarkers, and safety profile"],"prefix":"10.4103","volume":"72","author":[{"given":"Supriya","family":"Dabir","sequence":"first","affiliation":[{"name":"Rajan Retina Foundation, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthi","family":"Mohankumar","sequence":"additional","affiliation":[{"name":"Rajan Retina Foundation, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj G","family":"Khatri","sequence":"additional","affiliation":[{"name":"Rajan Retina Foundation, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohan","family":"Rajan","sequence":"additional","affiliation":[{"name":"Rajan Retina Foundation, Rajan Eye Care Hospital, Chennai, Tamil Nadu, India"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,12,22]]},"reference":[{"key":"R1-20260508","first-page":"844","article-title":"Global data on visual impairment in the year 2002","volume":"82","author":"Resnikoff","year":"2004","journal-title":"Bull World Health Organ"},{"key":"R2-20260508","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1755-3768.2008.01376.x","article-title":"The epidemiology of age-related macular degeneration in the Indian subcontinent","volume":"87","author":"Woo","year":"2009","journal-title":"Acta Ophthalmol"},{"key":"R3-20260508","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ophtha.2020.07.060","article-title":"Nonadherence or nonpersistence to intravitreal injection therapy for neovascular age-related macular degeneration: A mixed-methods systematic review","volume":"128","author":"Okada","year":"2021","journal-title":"Ophthalmology"},{"key":"R4-20260508","doi-asserted-by":"crossref","first-page":"257","DOI":"10.2147\/OPTH.S92616","article-title":"The emotional and physical impact of wet age-related macular degeneration: Findings from the wAMD patient and caregiver survey","volume":"10","author":"Varano","year":"2016","journal-title":"Clin Ophthalmol"},{"key":"R5-20260508","doi-asserted-by":"crossref","first-page":"2659","DOI":"10.2147\/DDDT.S378450","article-title":"Brolucizumab for the treatment of degenerative macular conditions: A review of clinical studies","volume":"16","author":"Karasavvidou","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"R6-20260508","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: Phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"key":"R7-20260508","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0002-9394(02)01825-1","article-title":"A computerized method of visual acuity testing: Adaptation of the early treatment of diabetic retinopathy study testing protocol","volume":"135","author":"Beck","year":"2003","journal-title":"Am J Ophthalmol"},{"issue":"5 Suppl","key":"R8-20260508","first-page":"741","article-title":"Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7","volume":"98","year":"1991","journal-title":"Ophthalmology"},{"key":"R9-20260508","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1136\/bjophthalmol-2020-318672","article-title":"Short-term real-world outcomes following intravitreal brolucizumab for neovascular AMD: SHIFT study","volume":"106","author":"Bulirsch","year":"2022","journal-title":"Br J Ophthalmol"},{"key":"R10-20260508","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1038\/s41433-020-1111-x","article-title":"Brolucizumab-early real-world experience: BREW study","volume":"35","author":"Sharma","year":"2021","journal-title":"Eye (Lond)"},{"key":"R11-20260508","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.2147\/OPTH.S256009","article-title":"Correlation of baseline visual acuity with outcomes of treatment with anti-VEGF in neovascular age-related macular degeneration","volume":"14","author":"Veluswamy","year":"2020","journal-title":"Clin Ophthalmol"},{"key":"R12-20260508","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1136\/bjophthalmol-2015-308077","article-title":"UK neovascular age-related macular degeneration database. Report 6: Time to retreatment after a pause in therapy. Outcomes from 92 976 intravitreal ranibizumab injections","volume":"100","author":"Madhusudhana","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R13-20260508","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1001\/jamaophthalmol.2020.7085","article-title":"Early experience with brolucizumab treatment of neovascular age-related macular degeneration","volume":"139","author":"Enriquez","year":"2021","journal-title":"JAMA Ophthalmol"},{"key":"R14-20260508","doi-asserted-by":"crossref","first-page":"3787","DOI":"10.2147\/OPTH.S328160","article-title":"Brolucizumab in neovascular age-related macular degeneration-Indian real-world experience: The BRAILLE study","volume":"15","author":"Chakraborty","year":"2021","journal-title":"Clin Ophthalmol"},{"key":"R15-20260508","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.3390\/jcm10132758","article-title":"Real-world experience with brolucizumab in wet age-related macular degeneration: The REBA study","volume":"10","author":"Bilgic","year":"2021","journal-title":"J Clin Med"},{"key":"R16-20260508","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ophtha.2019.11.004","article-title":"Consensus nomenclature for reporting neovascular age-related macular degeneration data: Consensus on neovascular age-related macular degeneration nomenclature study group","volume":"127","author":"Spaide","year":"2020","journal-title":"Ophthalmology"}],"container-title":["Indian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_927_23","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T16:27:41Z","timestamp":1786724861000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/IJO.IJO_927_23"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,22]]},"references-count":16,"journal-issue":{"issue":"Suppl 1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.4103\/ijo.ijo_927_23","relation":{},"ISSN":["0301-4738","1998-3689"],"issn-type":[{"value":"0301-4738","type":"print"},{"value":"1998-3689","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,22]]},"assertion":[{"value":"2023-04-07","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-08-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}